CERTIFICATIONS

(company name)	, through the undersigned authorized representative, hereby
certifies that:	
·	rates and forms may be disapproved, or otherwise give rise to applicable law or regulations. <i>See, e.g.,</i> 40 P.S. § 3801.304(b).
condition of the Company, or knowingly making ar Company, or knowingly omitting to make a true er	knowingly making any false material statement as to the financial my false entry of material fact in any book, report or statement of the ntry of any material fact pertaining to the Company in a book, report is an unfair method of competition and unfair or deceptive act or § 1171.5(a)(5).
AND further certifies, as to the below-referenced p	policy form, along with any related rate filing, that:
1. Rates a	and Forms Generally
P.L. 111-148,124 Stat. 119, and the Health Care an	he requirements of the Patient Protection and Affordable Care Act, d Education Reconciliation Act of 2010, P.L. 111-152, 124 Stat. 1051, and the regulations and federal guidance promulgated thereunder.
\square The Compliance Checklist submitted with the positive compliance of the complian	olicy form is true, correct and complete.
certify the representations of the Company as so	, hereby warrant that I have full, complete and final authority to et forth herein, that the certifications and representations set forth in bove regarding Certifications and Rates and Forms General) are true,
Policy Form #	
Date	Name and Title of Authorized Representative of the Company
	Signature of Authorized Representative of the Company

2. Mental Health and Substance Use Disorder Coverage Parity

as amended by the ACA, including the financial re	the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), equirements (FR), quantitative treatment limitations (QTLs), and non-ental Health or Substance Use Disorder Coverage (MH/SUD).
	NQTL applicable to MH/SUD benefits, as written and as to be applied, is ne classification, and that such parity is demonstrated by a documented
FR or QTL of that type applied to substan FR or QTL is considered to apply to "subs at least two-thirds of the benefits in the medical/surgical benefits in a classification	fits in any classification is not more restrictive than the predominant stially all medical/surgical benefits in the same classification, where: an stantially all" medical/surgical benefits in a classification if it applies to classification; and, if the FR or QTL applies to substantially all on, the predominant level of the FR or QTL is the level that applies to ical benefits in the classification subject to the FR or QTL.
to be in operation, any processes, strate NQTL to MH/SUD benefits in the classific	nefits in any classification, under the terms of the policy as written and egies, evidentiary standards, or other factors used in applying the cation are comparable to, and are intended to be applied no more es, evidentiary standards, or other factors used in applying the NQTL ification.
certify the representations of the Company as s	, hereby warrant that I have full, complete and final authority to et forth herein, that the certifications and representations set forth in h and Substance Use Disorder Coverage Parity) are true, correct, and
Policy Form #	
Date	Name and Title of Authorized Representative of the Company

Signature of Authorized Representative of the Company

3. Opioid Crisis Response

The Company provides coverage consistent with Act 146 of 2022 and the Department of Human Services' Bulletin Notices (as it relates to opioid use disorder treatment, MAB2024020601 (pa.gov)): ☐ Covers at least one of each type of Medication Assisted Treatment (MAT) for opioid addiction without preauthorization, including coverage of: □ buprenorphine/naloxone prescription drug combination product; ☐ injectable and oral naltrexone; ☐ methadone; and ☐ buprenorphine. ☐ Covers certain MAT (buprenorphine/naloxone prescription drug combination product; injectable and oral naltrexone; and methadone) as a pharmacy benefit on the policy's lowest non-preventive cost tier, as applicable. ☐ Covers sublingual buprenorphine opioid use disorder treatment that exceeds a daily dose of 24 mg/day ☐ The supporting clinical review criteria adopted by the Company are based on applicable nationally recognized medical standards, are consistent with applicable governmental guidelines, provide for the delivery of a health care service in a clinically appropriate type, frequency and setting and for a clinically appropriate duration, and reflect the current medical and scientific evidence regarding emerging procedures, clinical guidelines and best practices as articulated in independent, peer-reviewed medical literature. I, _____(authorized representative's name)_____, hereby warrant that I have full, complete and final authority to certify the representations of the Company as set forth herein, that the certifications and representations set forth in this Certification Form (relative to the Opioid Crisis Response) are true, correct, and complete. Policy Form # Date Name and Title of Authorized Representative of the Company

Signature of Authorized Representative of the Company